Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K
- PMID: 20633008
- PMCID: PMC2966545
- DOI: 10.1111/j.1365-2133.2010.09941.x
Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K
Abstract
Background: Severe psoriasis is associated with excess mortality and increased risk of cardiovascular death. Population-based data evaluating cause-specific mortality in patients with psoriasis are limited.
Objectives: To describe cause-specific mortality in patients with severe psoriasis.
Methods: We performed a cohort study from 1987 to 2002 of patients ≥18 years using the General Practice Research Database. We compared patients with a psoriasis code and a history of systemic therapy consistent with severe psoriasis (n=3603) with patients with no history of psoriasis (n=14,330). Age- and sex-adjusted Cox models were created for each of the leading causes of death defined by the Centers for Disease Control.
Results: Patients with severe psoriasis were at increased risk of death from cardiovascular disease [hazard ratio (HR) 1·57, 95% confidence interval (CI) 1·26-1·96], malignancies (HR 1·41, 95% CI 1·07-1·86), chronic lower respiratory disease (HR 2·08, 95% CI 1·24-3·48), diabetes (HR 2·86, 95% CI 1·08-7·59), dementia (HR 3·64, 95% CI 1·36-9·72), infection (HR 1·65, 95% CI 1·26-2·18), kidney disease (HR 4·37, 95% CI 2·24-8·53) and unknown/missing causes (HR 1·43, 95% CI 1·09-1·89). The absolute and excess risk of death was highest for cardiovascular disease (61·9 and 3·5 deaths per 1000 patient-years, respectively).
Conclusions: Severe psoriasis is associated with an increased risk of death from a variety of causes, with cardiovascular death being the most common aetiology. These patients were also at increased risk of death from causes not previously reported, such as infection, kidney disease and dementia. Additional studies are necessary to determine the degree to which excess causes of death are due to psoriasis, its treatments, associated behaviours, or other factors.
© The Authors. BJD © 2010 British Journal of Dermatology.
Conflict of interest statement
Comment in
-
Cause-specific mortality in patients with severe psoriasis.Br J Dermatol. 2010 Sep;163(3):449. doi: 10.1111/j.1365-2133.2010.09962.x. Br J Dermatol. 2010. PMID: 21053416 No abstract available.
Similar articles
-
All-cause and cause-specific mortality in patients with Behçet disease versus the general population.Br J Dermatol. 2024 May 17;190(6):858-866. doi: 10.1093/bjd/ljae051. Br J Dermatol. 2024. PMID: 38320213
-
Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study.Acta Derm Venereol. 2015 Sep;95(7):809-15. doi: 10.2340/00015555-2095. Acta Derm Venereol. 2015. PMID: 25766866
-
Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis.J Invest Dermatol. 2013 Oct;133(10):2340-2346. doi: 10.1038/jid.2013.149. Epub 2013 Feb 21. J Invest Dermatol. 2013. PMID: 23528816 Review.
-
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.Eur Heart J. 2010 Apr;31(8):1000-6. doi: 10.1093/eurheartj/ehp567. Epub 2009 Dec 27. Eur Heart J. 2010. PMID: 20037179 Free PMC article.
-
The risk of mortality in patients with psoriasis: results from a population-based study.Arch Dermatol. 2007 Dec;143(12):1493-9. doi: 10.1001/archderm.143.12.1493. Arch Dermatol. 2007. PMID: 18086997
Cited by
-
Proteomics in Psoriasis: Recent Advances.In Vivo. 2024 May-Jun;38(3):1000-1008. doi: 10.21873/invivo.13533. In Vivo. 2024. PMID: 38688625 Free PMC article. Review.
-
Nocebo effects in systemic therapies for adult plaque psoriasis: A systematic review and meta-analysis.Front Med (Lausanne). 2024 Mar 27;11:1373520. doi: 10.3389/fmed.2024.1373520. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38601115 Free PMC article.
-
Analysis of Clinical and Genetic Factors of Obesity and Psoriasis Concomitance-The Influence of Body Mass Composition, Prevalence of Mood Disorders, Environmental Factors and FTO Gene Polymorphisms (rs9939609, rs1558902).Biomedicines. 2024 Feb 25;12(3):517. doi: 10.3390/biomedicines12030517. Biomedicines. 2024. PMID: 38540130 Free PMC article.
-
Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 2030.Arch Dermatol Res. 2024 Mar 26;316(4):114. doi: 10.1007/s00403-024-02846-z. Arch Dermatol Res. 2024. PMID: 38530431
-
Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials.Front Med (Lausanne). 2024 Mar 6;11:1353893. doi: 10.3389/fmed.2024.1353893. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38510451 Free PMC article.
References
-
- Gelfand JM, Margolis DJ, Dattani H. The UK General Practice Research Database. In: Strom BL, editor. Pharmacoepidemiology. Fourth Edition ed. Philadelphila: John Wiley & Sons, Ltd; 2005. pp. 337–346.
-
- Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med. 2009 Dec;122(12):e1151–e1159. 1150. - PubMed
-
- Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. Mar;29(1):10–15. - PubMed
Publication types
MeSH terms
Grants and funding
- F32 AR056799/AR/NIAMS NIH HHS/United States
- R01 HL089744/HL/NHLBI NIH HHS/United States
- RC1AR058204/AR/NIAMS NIH HHS/United States
- T32 AR007465/AR/NIAMS NIH HHS/United States
- K23AR051125/AR/NIAMS NIH HHS/United States
- K23 AR051125/AR/NIAMS NIH HHS/United States
- R01HL089777/HL/NHLBI NIH HHS/United States
- RC1 AR058204-01/AR/NIAMS NIH HHS/United States
- F32 AR056799-02/AR/NIAMS NIH HHS/United States
- RC1 AR058204/AR/NIAMS NIH HHS/United States
- K23 AR051125-05/AR/NIAMS NIH HHS/United States
- R01 HL089744-02/HL/NHLBI NIH HHS/United States
- F32AR056799/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical